{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:21:15Z","timestamp":1758475275242},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00415-022-11280-y","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T18:02:45Z","timestamp":1658253765000},"page":"6021-6028","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Botulinum neurotoxin efficiency in dystonia associated with Parkinson\u2019s disease and atypical parkinsonism: a retrospective study with a self-reported improvement scale"],"prefix":"10.1007","volume":"269","clinical-trial-number":[{"clinical-trial-number":"nct04948684","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Arnaud","family":"Lapostolle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Houot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Mongin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Degos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"11280_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK (2013) Phenomenology and classification of dystonia: a consensus update: dystonia: phenomenology and classification. Mov Disord 28:863\u2013873","journal-title":"Mov Disord"},{"key":"11280_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-018-0023-6","volume":"4","author":"B Balint","year":"2018","unstructured":"Balint B, Mencacci NE, Valente EM, Pisani A, Rothwell J, Jankovic J, Vidailhet M, Bhatia KP (2018) Dystonia. Nat Rev Dis Primer 4:25","journal-title":"Nat Rev Dis Primer"},{"key":"11280_CR3","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303","journal-title":"Lancet"},{"key":"11280_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.05.001","volume":"132","author":"AS Shetty","year":"2019","unstructured":"Shetty AS, Bhatia KP, Lang AE (2019) Dystonia and Parkinson\u2019s disease: what is the relationship? Neurobiol Dis 132:104462","journal-title":"Neurobiol Dis"},{"key":"11280_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/jnnp-2013-307294","volume":"85","author":"AE Elia","year":"2014","unstructured":"Elia AE, Del Sorbo F, Romito LM, Barzaghi C, Garavaglia B, Albanese A (2014) Isolated limb dystonia as presenting feature of Parkin disease. J Neurol Neurosurg Psychiatry 85:827\u2013828","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11280_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts: dyskinesia in PD. Ann Neurol 84:797\u2013811","journal-title":"Ann Neurol"},{"key":"11280_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106\u20131117","journal-title":"Lancet Neurol"},{"key":"11280_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.23713","volume":"26","author":"GK Wenning","year":"2011","unstructured":"Wenning GK, Litvan I, Tolosa E (2011) Milestones in atypical and secondary Parkinsonisms: atypical\/secondary parkinsonism milestones. Mov Disord 26:1083\u20131095","journal-title":"Mov Disord"},{"key":"11280_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/WCO.0b013e3283632da6","volume":"26","author":"M Stamelou","year":"2013","unstructured":"Stamelou M, Hoeglinger GU (2013) Atypical parkinsonism: an update. Curr Opin Neurol 26:401\u2013405","journal-title":"Curr Opin Neurol"},{"key":"11280_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2019.07.030","volume":"66","author":"L Marsili","year":"2019","unstructured":"Marsili L, Bologna M, Kojovic M, Berardelli A, Espay AJ, Colosimo C (2019) Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord 66:25\u201333","journal-title":"Parkinsonism Relat Disord"},{"key":"11280_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/toxins13010058","volume":"13","author":"S Choudhury","year":"2021","unstructured":"Choudhury S, Baker MR, Chatterjee S, Kumar H (2021) Botulinum toxin: an update on pharmacology and newer products in development. Toxins 13:58","journal-title":"Toxins"},{"key":"11280_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/PL00007849","volume":"249","author":"R \u00c7akmur","year":"2002","unstructured":"\u00c7akmur R, Ozturk V, Uzunel F, Donmez B, Idiman F (2002) Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249:64\u201368","journal-title":"J Neurol"},{"key":"11280_CR13","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/WNL.58.12.1843","volume":"58","author":"R Forget","year":"2002","unstructured":"Forget R, Tozlovanu V, Iancu A, Boghen D (2002) Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology 58:1843\u20131846","journal-title":"Neurology"},{"key":"11280_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/mds.870100425","volume":"10","author":"V Lepore","year":"1995","unstructured":"Lepore V, Defazio G, Acquistapace D, Melpignano C, Pomes L, Lamberti P, Livrea P, Ferrari E (1995) Botulinum a toxin for the so-called apraxia of lid opening. Mov Disord 10:525\u2013526","journal-title":"Mov Disord"},{"key":"11280_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14219\/jada.archive.2000.0149","volume":"131","author":"E-K Tan","year":"2000","unstructured":"Tan E-K, Jankovic J (2000) treating severe bruxism with botulinum toxin. J Am Dent Assoc 131:211\u2013216","journal-title":"J Am Dent Assoc"},{"key":"11280_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.57.5.659","volume":"57","author":"N Giladi","year":"1994","unstructured":"Giladi N, Meer J, Honigman S (1994) The use of botulinum toxin to treat \u201cstriatal\u201d toes. J Neurol Neurosurg Psychiatry 57:659\u2013659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11280_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.10.009","volume":"46","author":"I Rieu","year":"2018","unstructured":"Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluch\u00e8re F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouhour F, Llinares E, Derost P, Marques A, Durif F (2018) Incobotulinum toxin A in Parkinson\u2019s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord 46:9\u201315","journal-title":"Parkinsonism Relat Disord"},{"key":"11280_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mds.1186","volume":"16","author":"C Cordivari","year":"2001","unstructured":"Cordivari C, Misra VP, Catania S, Lees AJ (2001) Treatment of dystonic clenched fist with botulinum toxin: treatment of dystonic clenched fist with BTXA. Mov Disord 16:907\u2013913","journal-title":"Mov Disord"},{"key":"11280_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mds.870100317","volume":"10","author":"C Pacchetti","year":"1995","unstructured":"Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G (1995) \u201cOff\u201d painful dystonia in Parkinson\u2019s disease treated with botulinum toxin. Mov Disord 10:333\u2013336","journal-title":"Mov Disord"},{"key":"11280_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs 21:677\u2013692","journal-title":"CNS Drugs"},{"issue":"3","key":"11280_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1212\/01.wnl.0000171857.09079.9f","volume":"65","author":"SN Azher","year":"2005","unstructured":"Azher SN, Jankovic J (2005) Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65(3):355\u2013359","journal-title":"Neurology"},{"key":"11280_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.toxicon.2015.06.004","volume":"107","author":"KL Bertram","year":"2015","unstructured":"Bertram KL, Stirpe P, Colosimo C (2015) Treatment of camptocormia with botulinum toxin. Toxicon 107:148\u2013153","journal-title":"Toxicon"},{"key":"11280_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione F (2016) Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in Clinical Practice. Toxins 8:65","journal-title":"Toxins"},{"key":"11280_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","volume":"4","author":"S Nakagawa","year":"2013","unstructured":"Nakagawa S, Schielzeth H (2013) A general and simple method for obtaining R 2 from generalized linear mixed-effects models. Methods Ecol Evol 4:133\u2013142","journal-title":"Methods Ecol Evol"},{"key":"11280_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/03007995.2021.1965975","volume":"37","author":"DD Mitsikostas","year":"2021","unstructured":"Mitsikostas DD, Dekundy A, Hanschmann A, Althaus M, Scheschonka A, Pagan F, Jankovic J (2021) Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na\u00efve subjects. Curr Med Res Opin 37:1761\u20131768","journal-title":"Curr Med Res Opin"},{"key":"11280_CR26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/mds.23658","volume":"26","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Comella C, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord 26:1521\u20131528","journal-title":"Mov Disord"},{"key":"11280_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","volume":"120","author":"DD Truong","year":"2013","unstructured":"Xeomin US Blepharospasm Study Group, Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH (2013) Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm. J Neural Transm 120:1345\u20131353","journal-title":"J Neural Transm"},{"key":"11280_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"1996","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S (1996) NT 201 Blepharospasm Study Team (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm Vienna Austria 113:303\u2013312","journal-title":"J Neural Transm Vienna Austria"},{"key":"11280_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-10995-2","author":"C Ledda","year":"2022","unstructured":"Ledda C, Artusi CA, Tribolo A, Rinaldi D, Imbalzano G, Lopiano L, Zibetti M (2022) Time to onset and duration of botulinum toxin efficacy in movement disorders. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-10995-2","journal-title":"J Neurol"},{"key":"11280_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/cjn.2016.279","volume":"43","author":"VA Bruno","year":"2016","unstructured":"Bruno VA, Fox SH, Mancini D, Miyasaki JM (2016) Botulinum toxin use in refractory pain and other symptoms in Parkinsonism. Can J Neurol Sci J Can Sci Neurol 43:697\u2013702","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"11280_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2340\/16501977-2094","volume":"48","author":"A Gupta","year":"2016","unstructured":"Gupta A, Visvanathan R (2016) Botulinum toxin for foot dystonia in patients with Parkinson\u2019s disease having deep brain stimulation: a case series and a pilot study. J Rehabil Med 48:559\u2013562","journal-title":"J Rehabil Med"},{"key":"11280_CR32","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/PPA.S141060","volume":"11","author":"B Leplow","year":"2017","unstructured":"Leplow B, Eggebrecht A, Pohl J (2017) Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia. Patient Prefer Adherence 11:1555\u20131563","journal-title":"Patient Prefer Adherence"},{"key":"11280_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","volume":"11","author":"S Bellows","year":"2019","unstructured":"Bellows S, Jankovic J (2019) Immunogenicity associated with botulinum toxin treatment. Toxins 11:491","journal-title":"Toxins"},{"key":"11280_CR34","doi-asserted-by":"publisher","first-page":"175628641989207","DOI":"10.1177\/1756286419892078","volume":"12","author":"H Hefter","year":"2019","unstructured":"Hefter H, Rosenthal D, Bigalke H, Moll M (2019) Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Ther Adv Neurol Disord 12:175628641989207","journal-title":"Ther Adv Neurol Disord"},{"key":"11280_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/toxins12080499","volume":"12","author":"S Samadzadeh","year":"2020","unstructured":"Samadzadeh S, \u00dcrer B, Brauns R, Rosenthal D, Lee J-I, Albrecht P, Hefter H (2020) Clinical implications of difference in antigenicity of different botulinum neurotoxin type A preparations: clinical take-home messages from our research pool and literature. Toxins 12:499","journal-title":"Toxins"},{"key":"11280_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/JEP.S265282","volume":"13","author":"A Fabbrini","year":"2021","unstructured":"Fabbrini A, Guerra A (2021) Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia. J Exp Pharmacol 13:469\u2013485","journal-title":"J Exp Pharmacol"},{"key":"11280_CR37","first-page":"1109","volume":"125","author":"TN Tran","year":"2018","unstructured":"Tran TN, Vo TNN, Frei K, Truong DD (2018) Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm Vienna Austria 1996 125:1109\u20131117","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"11280_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuro.2021.07.006","volume":"86","author":"C Zheng","year":"2021","unstructured":"Zheng C, Zhang F (2021) New insights into pathogenesis of l-DOPA-induced dyskinesia. Neurotoxicology 86:104\u2013113","journal-title":"Neurotoxicology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11280-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T12:07:43Z","timestamp":1665490063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["11280"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11280-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by local Ethics Committee (CLEA-2021\u2013167) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}